About Cargo Therapeutics
Cargo Therapeutics is a company based in San Mateo (United States) founded in 2021 by Louai Labanieh, Robbie Majzner, and Nancy Goodman was acquired by Concentra Biosciences in July 2025. Cargo Therapeutics has raised $200 million across 1 funding round from investors including Nextech Systems, T. Rowe Price and Janus Henderson Investors. The company has 42 employees as of December 31, 2022. Cargo Therapeutics offers products and services including CRG-023. Cargo Therapeutics operates in a competitive market with competitors including Senti Biosciences, Caribou Biosciences, Poseida Therapeutics, Immunocore and Juno Therapeutics, among others.
- Headquarter San Mateo, United States
- Employees 42 as on 31 Dec, 2022
- Founders Louai Labanieh, Robbie Majzner, Nancy Goodman
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cargo Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$200 M (USD)
in 1 rounds
-
Latest Funding Round
$200 M (USD), Series A
Feb 09, 2023
-
Investors
Nextech Systems
& 15 more
-
Employee Count
42
as on Dec 31, 2022
-
Acquired by
Concentra Biosciences
(Jul 08, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cargo Therapeutics
Cargo Therapeutics offers a comprehensive portfolio of products and services, including CRG-023.
Platform for developing allogeneic CAR T-cell therapies to treat cancer.
People of Cargo Therapeutics
Unlock access to complete
Funding Insights of Cargo Therapeutics
Cargo Therapeutics has successfully raised a total of $200M through 1 strategic funding round. The most recent funding activity was a Series A round of $200 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cargo Therapeutics
Cargo Therapeutics has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Nextech Systems, T. Rowe Price and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Cargo Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cargo Therapeutics
Investment portfolio details for Cargo Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cargo Therapeutics
Detailed financials for Cargo Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cargo Therapeutics Comparisons
Peer comparison for Cargo Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cargo Therapeutics
Cargo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Caribou Biosciences, Poseida Therapeutics, Immunocore and Juno Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
Detailed competitors of Cargo Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cargo Therapeutics
Complete news archive for Cargo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cargo Therapeutics
Cargo Therapeutics was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Cargo Therapeutics is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Cargo Therapeutics is a funded company, having raised a total of $200M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Cargo Therapeutics is 42.
Cargo Therapeutics was founded in 2021 and is based in San Mateo, United States. Focus is placed on the biotechnology sector, where cell-based therapeutics are developed for cancer treatment. CAR T-cell therapies, including CD22 CAR T and multi-specific CAR T candidates, are offered for addressing hematological malignancies and solid tumors. Operations center on advancing these drug candidates through research and development.
Cargo Therapeutics's top competitors include Immunocore, Juno Therapeutics and Lyell Immunopharma.
Cargo Therapeutics offers CRG-023.
Cargo Therapeutics has 16 investors. Key investors include Nextech Systems, T. Rowe Price, Janus Henderson Investors, RTW Investments, and Piper Sandler.